Following transradial percutaneous coronary interventions (PCI), the radial artery can occasionally occlude, potentially resulting in serious complications. Radial occlusion is treated by applying compression, but clinicians have no idea whether nor how much blood is flowing through the artery. Moreover, once an occlusion happens in the radial artery, it cannot be used again as an access site in the future.
A new device called IdaFlo Tr from IdaHealth, a company out of Bonita Springs, Florida, has just been revealed at the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EuroPCR) in Paris, France. The wireless device is placed around the wrist of the patient, near the access site, and is then calibrated. Following, it continuously monitors blood flow through the artery, raising an alarm if it detects a slow down in flow. Multiple of these devices can be used, allowing nurses to monitor groups of patients following their procedures.
The IdaFlo Tr was already tested in a proof-of-concept study on three coronary patients, and the initial results have shown that it can detect abnormal blood flow post coronary catheterization. This allowed clinicians to intelligently adjust the compression device that was used, closing the access site and preventing any occlusions.catheterization procedure, allowing a clinician to adjust the compression device that is commonly used to close the puncture site in the recovery room and, therefore, prevent occlusions.
“The advantages of IdaFlo Tr are remarkable. It adds eyes to a blind procedure,” said Dr. Giovanni Amoroso, an interventional cardiologist in Amsterdam, The Netherlands, in a statement. “Preliminary results confirm proof of concept and the value IdaFlo Tr may provide to physicians, nurses and patients. IdaFlo Tr has the potential to standardize transradial angioplasty monitoring.”
“With lower all-cause mortality, vascular complications and major bleeding events, transradial access in PCI has become a prevalent method for interventional cardiologist,” added David Camp, President, CEO and Co-founder of IdaHealth and General Manager of MACCO International Limited consulting firm. “RAO is the most common vascular complication of the transradial approach and there is no standard of care to minimize the incidence of RAO. IdaFlo Tr has the potential to decrease the incidence of RAO, increase safety of transradial angioplasty PCI procedures and reduce workload for physicians and nurses.”